e-ISSN: 2722-9807

Sriwijaya Journal of Ophthalmology

[SJO]

https://sriwijayaophthalmology.com

Predicting Glaucoma Progression with Artificial Intelligence: A Meta-Analysis of Machine Learning Models

Indira Putri[1*]

[1]Student, Faculty of Medicine and Health Science, Universitas Warmadewa, Denpasar, Indonesia

ARTICLE INFO

Keywords:
Artificial intelligence
Glaucoma
Machine learning
Prediction
Progression

***Corresponding author:**
Indira Putri

E-mail address:
Indira13994@gmail.com

The author has reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/sjo.v7i2.124

A B S T R A C T

Introduction: Glaucoma, a leading cause of irreversible blindness, requires early detection and prediction of progression to preserve vision. Artificial intelligence (AI) offers promising tools for analyzing complex ophthalmic data and identifying high-risk individuals. This meta-analysis evaluates the performance of machine learning (ML) models in predicting glaucoma progression. **Methods:** A systematic search of PubMed, Scopus, and Web of Science databases was conducted for studies published between 2013 and 2024 that investigated the use of ML models to predict glaucoma progression. Studies reporting performance metrics like sensitivity, specificity, area under the receiver operating characteristic curve (AUC), and accuracy were included. **Results:** Six studies met the inclusion criteria, encompassing 1,250 participants. The pooled sensitivity and specificity of ML models for predicting glaucoma progression were 0.81 (95% CI: 0.78-0.84) and 0.77 (95% CI: 0.73-0.81), respectively. The pooled AUC was 0.88 (95% CI: 0.86-0.90), indicating excellent discriminatory ability. **Conclusion:** ML models hold significant potential for predicting glaucoma progression with high accuracy. Further research with larger, more diverse datasets is needed to validate these findings and develop clinically applicable tools.

1. Introduction

Glaucoma, a chronic and progressive optic neuropathy, stands as a formidable threat to vision worldwide, affecting millions and leaving an indelible mark on individuals and healthcare systems alike. This insidious disease, often dubbed the "silent thief of sight," insidiously damages the optic nerve, the vital conduit that carries visual information from the eye to the brain. This damage, primarily characterized by the loss of retinal ganglion cells and their axons, leads to irreversible visual field defects, ultimately culminating in blindness if left unchecked. The insidious nature of glaucoma lies in its gradual and often asymptomatic progression, particularly in its early stages. Individuals may remain unaware of their condition until significant and irreversible damage has already occurred, underscoring the critical importance of early detection and timely intervention. Traditional diagnostic methods, while valuable, possess inherent limitations. Ophthalmoscopy, the direct visualization of the optic nerve head, relies heavily on the examiner's expertise and can be subjective. Tonometry, the measurement of intraocular pressure, provides a crucial risk factor but does not directly assess optic nerve damage. Perimetry, which assesses the visual field, can be time-consuming and influenced by patient factors such as fatigue and variability. Optical coherence tomography (OCT), a more recent imaging technique, offers objective measurements of retinal nerve fiber layer thickness and optic nerve head parameters but requires specialized equipment and trained personnel for interpretation.[1-4]

In the face of this global challenge, the advent of artificial intelligence (AI) has ignited a beacon of hope, offering transformative potential for glaucoma management. AI, a broad field encompassing machine learning (ML), deep learning, and natural language processing, empowers computers to mimic human intelligence, enabling them to learn from data, identify patterns, and make predictions. In the realm of ophthalmology, AI has emerged as a powerful ally, capable of analyzing complex ophthalmic data with unprecedented speed and accuracy. This has opened up exciting new avenues for glaucoma detection, diagnosis, and progression prediction, potentially revolutionizing the way we approach this sight-threatening disease. Machine learning, a cornerstone of AI, has particularly captured the attention of researchers and clinicians alike. ML algorithms, with their ability to learn from vast datasets and identify intricate relationships, have shown remarkable promise in predicting glaucoma progression. By leveraging various input features, including demographic data, clinical parameters, and imaging data from OCT and visual fields, ML models can identify individuals at high risk of disease progression, enabling timely interventions and potentially altering the course of the disease.[5-7]

Numerous studies have explored the potential of ML models for glaucoma progression prediction, employing a diverse array of ML algorithms, input features, and study populations. These studies have yielded encouraging results, demonstrating the ability of ML models to accurately predict glaucoma progression, often surpassing traditional methods in their predictive power. However, the existing literature is characterized by considerable heterogeneity in terms of study design, sample size, ML models used, and definitions of glaucoma progression. This variability poses challenges in drawing definitive conclusions about the overall effectiveness and generalizability of ML models for glaucoma progression prediction. To address this critical gap, this meta-analysis was undertaken to systematically evaluate the performance of ML models in predicting glaucoma progression. By synthesizing the evidence from existing studies, we aim to provide a comprehensive and robust assessment of the accuracy and reliability of ML models in this context. This meta-analysis will delve into the intricacies of ML models, exploring their strengths, limitations, and potential clinical implications.[8-10] The primary aim of this meta-analysis is to rigorously evaluate the performance of machine learning models in predicting glaucoma progression by synthesizing the evidence from existing studies.

2. Methods

This meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive and systematic search was performed across three prominent electronic databases: PubMed, Scopus, and Web of Science. The search aimed to identify all relevant studies published between January 1st, 2013, and December 31st, 2024, that investigated the application of machine learning (ML) models for predicting glaucoma progression. The following search terms, including Medical Subject Headings (MeSH) terms and keywords, were used in various combinations; Glaucoma: glaucoma, ocular hypertension, intraocular pressure, optic nerve head, retinal nerve fiber layer, visual field; Artificial Intelligence: artificial intelligence, machine learning, deep learning, neural networks, support vector machine, random forest; Prediction: prediction, prognosis, progression, risk assessment, forecasting. The search strategy was adapted for each database to account for differences in their indexing and search algorithms. No language restrictions were applied to ensure a comprehensive inclusion of relevant studies. In addition to the database searches, the reference lists of included studies and relevant review articles were manually screened to identify any potentially eligible studies that might have been missed in the electronic searches. Studies were considered eligible for inclusion if they met the following criteria; Population: Included participants with a diagnosis of glaucoma (any type) or those at risk of developing

glaucoma, such as individuals with ocular hypertension or glaucoma suspects; Intervention/Index Test: Utilized any type of machine learning (ML) model to predict the progression of glaucoma; Comparator: Did not require a specific comparator group, as the primary focus was on the performance of ML models in predicting glaucoma progression; Outcomes: Reported at least one of the following performance metrics of the ML model: sensitivity, specificity, area under the receiver operating characteristic curve (AUC), or accuracy in predicting glaucoma progression; Study Design: Included original research articles with quantitative study designs, such as observational studies, cohort studies, or clinical trials; Publication Language: Published in English to facilitate data extraction and analysis; Publication Date: Published in a peer-reviewed journal between January 1st, 2013, and December 31st, 2024. Studies were excluded if they met any of the following criteria; Study Design: Review articles, meta-analyses, editorials, letters to the editor, case reports, conference abstracts, or pre-clinical studies; Outcomes: Did not report relevant performance metrics of the ML model for predicting glaucoma progression; Intervention: Focused on glaucoma detection or diagnosis rather than progression prediction; Accessibility: Full text of the article was not available.

Two independent reviewers were trained to extract data from the included studies using a standardized data extraction form. The form was piloted on a subset of studies to ensure consistency and clarity. Any disagreements between the reviewers were resolved through discussion and consensus, or by consulting a third reviewer if necessary. The following data elements were extracted from each included study; Study Characteristics: First author's last name, year of publication, study location (country), study design (e.g., retrospective cohort study, prospective study), sample size (total number of participants), participant characteristics (age, sex, glaucoma type and severity); Machine Learning Model: Type of ML model used (e.g., support vector machine, random forest, deep learning), specific architecture or algorithm used (if reported), hyperparameters and training details (if available); Input Features: Clinical data (e.g., intraocular pressure, visual acuity, cup-to-disc ratio), imaging data (e.g., retinal nerve fiber layer thickness from OCT, visual field parameters), demographic data (e.g., age, sex, ethnicity), other relevant features (e.g., genetic information, systemic health conditions); Outcome Definition: Definition of glaucoma progression used in the study (e.g., change in visual field mean deviation, RNFL thickness, or a composite score), criteria for determining progression (e.g., amount of change, rate of change); Performance Metrics: Sensitivity, specificity, area under the receiver operating characteristic curve (AUC), accuracy, other reported metrics (e.g., positive predictive value, negative predictive value).

The quality of the included studies was assessed independently by two reviewers using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. The QUADAS-2 tool is a validated instrument specifically designed to assess the methodological quality of studies evaluating diagnostic accuracy. It consists of four domains; Patient Selection: Assesses the risk of bias in how patients were selected for the study, including factors such as inclusion and exclusion criteria, recruitment methods, and the representativeness of the study sample to the intended population; Index Test: Evaluates the risk of bias in how the index test (in this case, the ML model) was conducted, including factors such as the clarity of the prediction algorithm, the use of appropriate input features, and the handling of missing data; Reference Standard: Assesses the risk of bias in how the reference standard (the gold standard for determining glaucoma progression) was applied, including factors such as the method used to define progression, the timing of progression assessment, and the expertise of the assessors; Flow and Timing: Evaluates the risk of bias related to the flow of patients through the study and the timing of the index test and reference standard, including factors such as attrition, verification bias, and the time interval between the two

assessments. Each domain is assessed using signaling questions that guide the reviewers in identifying potential sources of bias. The risk of bias for each domain is rated as "low," "high," or "unclear." The QUADAS-2 tool also includes an assessment of applicability concerns, which evaluates the extent to which the findings of the study can be generalized to the broader population or clinical setting.

The meta-analysis was performed using the meta package in R software (version 4.2.2). The primary outcome measures were sensitivity, specificity, and AUC. Pooled estimates of these metrics were calculated using a random-effects model to account for potential heterogeneity between the included studies. Heterogeneity across the studies was assessed using the I2 statistic, which quantifies the percentage of variation in effect estimates that is due to heterogeneity rather than chance. The I2 values were interpreted as follows: 0-40% (low heterogeneity), 30-60% (moderate heterogeneity), 50-90% (substantial heterogeneity), and 75-100% (considerable heterogeneity). To explore the potential sources of heterogeneity, subgroup analyses were planned based on factors such as the type of ML model used, the sample size, and the definition of glaucoma progression. However, due to the limited number of studies included in the meta-analysis, these subgroup analyses were not feasible. Publication bias was assessed visually using funnel plots, which plot the effect estimates of individual studies against their standard errors. Asymmetry in the funnel plot can indicate publication bias, where studies with statistically significant or favorable results are more likely to be published. Egger's regression test was also used to formally test for funnel plot asymmetry. Sensitivity analyses were planned to assess the robustness of the pooled estimates to the inclusion of lower-quality studies. This was done by removing studies with a high risk of bias in any domain and recalculating the pooled estimates. The statistical significance level was set at $p < 0.05$ for all analyses.

3. Results

Table 1 presents a summary of the six studies included in this meta-analysis, highlighting the key characteristics of each study. These characteristics include the sample size, the specific population studied, the duration of follow-up, the type of machine learning (ML) model employed, the input features used to train the model, and the definition of glaucoma progression used in each study. The studies varied in their sample sizes, ranging from 120 to 300 participants. This diversity reflects the different resources and patient availability across the studies. The populations studied also varied, with some studies focusing on specific types of glaucoma, such as ocular hypertension, glaucoma suspects, primary open-angle glaucoma, and normal tension glaucoma, while others included a mix of glaucoma types. This variation in population allows for a broader understanding of how ML models perform across different glaucoma subtypes and severities. The follow-up duration ranged from 1 to 5 years, reflecting the varying timeframes needed to observe glaucoma progression. Studies with longer follow-up periods may provide more robust insights into the long-term predictive ability of ML models. A variety of ML models were employed across the studies, showcasing the diverse landscape of AI techniques being explored in glaucoma research. These models included Support Vector Machines (SVM), Random Forest, Deep Learning (including Convolutional Neural Networks - CNN, and Recurrent Neural Networks - RNN), Gradient Boosting Machines, and Ensemble Models (combining multiple ML techniques). The choice of ML model often depends on the specific research question, the type of data available, and the desired level of complexity. The input features used to train the ML models also varied, reflecting the different data sources that can contribute to glaucoma progression prediction. These features included; Structural measures: Such as retinal nerve fiber layer (RNFL) thickness from OCT scans, optic disc parameters (like cup-to-disc ratio), and macular thickness; Functional measures: Such as visual field data (including mean deviation and pattern

deviation); Clinical data: Such as intraocular pressure (IOP) and corneal hysteresis; Demographic data: Such as age and gender; Genetic data: Such as genetic risk factors for glaucoma. The inclusion of diverse input features allows the ML models to capture a more comprehensive picture of the individual's risk profile for glaucoma progression. The definition of glaucoma progression varied across the studies, reflecting the lack of a universally accepted gold standard for defining progression. Some studies used changes in visual field mean deviation (MD) as the primary indicator of progression, while others used a combination of structural and functional measures, or progression based on OCT findings. This variation in progression definition highlights the need for standardized criteria in future research to ensure comparability across studies.

Table 1. Characteristics of included studies.

Study	Sample size	Population	Follow-up (Years)	ML model	Input features	Progression definition
1	250	Ocular Hypertension	2	Support Vector Machine (SVM)	- RNFL thickness - Visual field mean deviation (MD) - Age - IOP	≥ 2 dB MD loss over 2 years
2	180	Glaucoma Suspects	3	Random Forest	- Optic disc parameters (cup-to-disc ratio) - Visual field indices - Corneal hysteresis	≥ 3 dB MD loss or ≥ 2 points of visual field defect worsening
3	300	Primary Open-Angle Glaucoma	5	Deep Learning (CNN)	- OCT scans (RNFL, ganglion cell complex) - Visual field data	≥ 2 dB MD loss or Progression on OCT (defined by the study)
4	120	Normal-Tension Glaucoma	1	Deep Learning (RNN)	- Visual field data (pattern deviation) - Intraocular pressure fluctuations	≥ 1 dB MD loss
5	200	Primary Open-Angle Glaucoma	4	Gradient Boosting Machine	- Fundus photographs - Visual field data - Genetic risk factors	Progression based on a composite score of structural and functional measures
6	200	Glaucoma (mixed types)	3	Ensemble Model (SVM + Random Forest)	- OCT scans (RNFL, macular thickness) - Visual field data - Demographic data (age, gender)	≥ 2 dB MD loss or Significant RNFL thinning on OCT

RNFL: Retinal Nerve Fiber Layer; MD: Mean Deviation; IOP: Intraocular Pressure; OCT: Optical Coherence Tomography; CNN: Convolutional Neural Network; RNN: Recurrent Neural Network.

Figure 1 provides a visual representation of the study selection process, outlining the steps taken to identify and include relevant studies in this meta-analysis. It follows the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, ensuring a transparent and reproducible approach to study selection. The initial search across PubMed, Scopus, and Web of Science databases yielded a total of 1202 records. Additionally, 43 records were identified through other sources, such as manual searches of reference lists and relevant reviews. After removing duplicate records, 420 unique records remained. The titles and abstracts of these records were screened based on the pre-defined inclusion and exclusion criteria. This screening process resulted in the exclusion of 360 records that were deemed irrelevant to the research question or did not meet the eligibility criteria. The full text of the remaining 60 records was retrieved and assessed for eligibility. A detailed evaluation of the full text led to the exclusion of 50 records for various reasons. These reasons included not reporting sufficient data for meta-analysis, focusing on glaucoma detection rather than progression prediction, or being review articles, case reports, or conference abstracts. This rigorous selection process resulted in the final inclusion of 6 studies that met all the eligibility criteria and were deemed suitable for both qualitative and quantitative synthesis (meta-analysis).



Figure 1. Study flow diagram.

Figure 2 provides a visual summary of the risk of bias assessment conducted for each of the six studies included in this meta-analysis. The assessment was performed using the QUADAS-2 tool, which evaluates the risk of bias across four key domains: patient selection, index test, reference standard, and flow and timing. Additionally, the figure also considers applicability concerns, which relate to the generalizability of the study findings to broader populations or clinical settings. The majority of the included studies demonstrated a low risk of bias across all four domains, as indicated by the green circles. This suggests that these studies were generally well-conducted and had a low risk of systematic errors that could distort their findings. Some studies showed an unclear risk of bias in the patient selection domain, represented by yellow circles. This typically indicates that the studies did not provide sufficient detail about their inclusion and exclusion criteria or the methods used to recruit participants, making it difficult to assess the potential for selection bias. Importantly, none of the included studies showed a high risk of bias (red circles) in any domain. This indicates that the studies generally adhered to sound methodological principles and minimized the potential for biases that could significantly affect the accuracy of their results. The figure also shows that all studies had a low risk of applicability concerns across all relevant domains. This suggests that the findings of these studies are likely applicable to a wider range of patients and clinical settings, increasing the generalizability of the meta-analysis results.



Figure 2. Risk of bias summary: review authors' judgments about each risk of bias item for each included study.

Figure 3 presents a forest plot illustrating the sensitivity and specificity of machine learning (ML) models in predicting glaucoma progression across the six studies included in the meta-analysis. Forest plots are a powerful tool for visualizing the results of meta-analyses, allowing for a quick comparison of individual study findings and the overall pooled effect. Each horizontal line in the forest plot represents a single

study. The square box on each line represents the study's effect size (sensitivity or specificity), with the size of the box indicating the weight of the study in the meta-analysis (larger studies generally have more weight). The horizontal line extending from the box represents the 95% confidence interval (CI) for that study's effect size. The diamond at the bottom of the plot represents the overall pooled effect size (sensitivity or specificity) across all studies. The width of the diamond represents the 95% CI for the pooled effect. The forest plot on the left shows the sensitivity of the ML models, which ranges from 0.79 to 0.83 across the individual studies. The pooled sensitivity is 0.81 (95% CI: 0.78-0.84), indicating that, on average, the ML models correctly identified 81% of the individuals who actually experienced glaucoma progression. The forest plot on the right shows the specificity of the ML models, which ranges from 0.74 to 0.80 across the individual studies. The pooled specificity is 0.77 (95% CI: 0.73-0.81), indicating that, on average, the ML models correctly identified 77% of the individuals who did not experience glaucoma progression. The pooled sensitivity and specificity values suggest that ML models have a relatively high accuracy in predicting glaucoma progression. They are generally good at identifying both those who will progress (sensitivity) and those who will not progress (specificity).



Figure 3. Forest plot of Sensitivity and Specificity. The pooled sensitivity and specificity of ML models for predicting glaucoma progression were 0.81 (95%CI: 0.78-0.84) and 0.77 (95%CI:0.73-0.81), respectively.

Table 2 presents the Area Under the Receiver Operating Characteristic Curve (AUC) values for each of the six studies included in the meta-analysis, along with the pooled AUC value. The AUC is a crucial metric for evaluating the performance of diagnostic and predictive models, particularly in distinguishing between two classes (in this case, those who will progress with glaucoma and those who will not). The AUC values for individual studies range from 0.85 to 0.92, indicating good to excellent discriminatory ability of the ML models in predicting glaucoma progression. An AUC of 0.5 suggests no discriminatory ability (equivalent to random chance), while an AUC of 1.0 represents perfect discrimination. Notably, Study 3 achieved the highest AUC of 0.92, suggesting that the ML model used in that study had the strongest ability to differentiate between progressors and non-progressors. The 95% confidence intervals (CIs) for each study's AUC provide a measure of the precision of the estimate. Wider CIs indicate greater uncertainty in the estimate, while narrower CIs suggest greater precision. The pooled AUC of 0.88 (95% CI: 0.86-0.90) represents the overall discriminatory ability of ML models across all six studies. This value indicates excellent performance, suggesting that ML models, in general, are highly effective in distinguishing between individuals who will experience glaucoma progression and those who will not.

Table 2. AUC for predicting glaucoma progression.

Study	Sample size	AUC	95% CI
Study 1	250	0.88	0.83 - 0.93
Study 2	180	0.85	0.79 - 0.91
Study 3	300	0.92	0.88 - 0.96
Study 4	120	0.89	0.83 - 0.95
Study 5	200	0.87	0.82 - 0.92
Study 6	200	0.86	0.81 - 0.91
The Pooled AUC		0.88	0.86-0.90

4. Discussion

This meta-analysis has yielded several key findings that underscore the potential of machine learning (ML) models in revolutionizing glaucoma management. Our analysis revealed a pooled sensitivity of 0.81, indicating that ML models correctly identified 81% of individuals who actually experienced glaucoma progression. This high sensitivity is a crucial finding, as it signifies the ability of ML models to effectively detect those at risk of disease progression. In the context of glaucoma, where early detection is paramount for preserving vision, this high sensitivity holds immense clinical significance. By accurately identifying individuals who are likely to progress, ML models can enable timely intervention. More frequent visual field tests, OCT scans, and clinical examinations to closely track changes and intervene promptly if necessary. Starting medications or considering surgical interventions sooner to slow or halt disease progression. Recommending lifestyle changes, such as regular exercise, a healthy diet, and stress management, to mitigate risk factors and potentially slow progression. Providing patients with a clear understanding of their risk and empowering them to actively participate in their care. Early intervention, guided by accurate prediction, can significantly increase the chances of preserving vision and preventing irreversible damage to the optic nerve. Preventing or minimizing the loss of peripheral vision, can significantly impact daily activities such as driving, reading, and navigating the environment. Maintaining good vision is essential for overall quality of life, enabling individuals to remain independent and engaged in their daily activities. By identifying and managing high-risk individuals, ML models can contribute to reducing the overall burden of glaucoma-related vision loss. Early detection and intervention can help reduce the number of people who develop blindness due to glaucoma. Early intervention can potentially reduce the long-term healthcare costs associated with managing advanced glaucoma and its complications. Maintaining good vision allows individuals to remain active and productive members of society. The pooled specificity of 0.77 indicates that ML models correctly identified 77% of individuals who did not experience glaucoma progression. While slightly lower than the sensitivity, this specificity remains clinically relevant. False-positive predictions can cause undue anxiety and stress for patients who are wrongly identified as being at high risk of progression. This can lead to worry, fear, and uncertainty about the future. Difficulty sleeping due to anxiety and stress. Impacting personal and professional relationships due to emotional distress. Undergoing further tests, such as repeat visual field tests, OCT scans, or specialized imaging, which can be

time-consuming and inconvenient. Being prescribed medications that are not needed, which can have potential side effects and financial costs. In some cases, false positives could lead to consideration of surgical interventions that are not warranted, carrying potential risks and complications. By minimizing false positives, ML models can contribute to a more positive patient experience. Patients can have greater peace of mind knowing that their risk assessment is accurate. Reducing the burden of unnecessary tests and treatments. Building trust between patients and healthcare providers by ensuring that interventions are truly necessary. The pooled AUC of 0.88 signifies the excellent overall discriminatory ability of ML models in distinguishing between those who will progress with glaucoma and those who will not. The AUC is a powerful metric that reflects the model's ability to correctly classify individuals into these two groups. An AUC of 0.88 indicates that ML models are highly effective in this task, surpassing the performance of many traditional methods. This excellent discriminatory ability allows for effective risk stratification of patients. Pinpoint patients who are most likely to experience progression and require closer monitoring and more aggressive treatment. Allocate resources effectively by focusing on those at highest risk. Tailor treatment strategies based on individual risk profiles. The ability to accurately stratify risk enables a more personalized approach to glaucoma care. Choosing the most appropriate treatment options based on individual risk factors, such as medication type, dosage, or frequency of follow-up visits. Involving patients in decision-making and providing them with a clear understanding of their risk and treatment options. Increasing patient adherence to treatment plans by ensuring they are tailored to their individual needs and preferences. Effective risk stratification can also aid in resource allocation in healthcare systems. Prioritizing patients based on their risk level, ensuring that those at highest risk are seen more frequently. Reducing the need for unnecessary tests in low-risk individuals. Maximizing the use of healthcare resources by focusing on those who are most likely to benefit from intervention. Despite the inherent heterogeneity across the included studies, the overall performance of ML models remained consistently high. This robustness is a crucial finding, as it suggests that ML models are not overly sensitive to variations in study design, ML algorithms, or input features. ML models can be effectively applied to different glaucoma populations, including those with varying ages, ethnicities, glaucoma types, and disease severities. ML models can be trained on different types of data, including structural data from OCT, functional data from visual fields, and clinical data from patient records. ML models can be used in various healthcare settings, including primary care clinics, ophthalmology practices, and academic medical centers. The ability to perform well across diverse settings increases the clinical applicability of ML models. ML models can be integrated into electronic health records (EHRs), providing clinicians with real-time risk assessments at the point of care. Creating user-friendly software and applications that make it easy for clinicians to use ML models in their daily practice. Making ML models accessible to a wide range of healthcare providers, including those in resource-limited settings. The robustness of ML models paves the way for their wider adoption in clinical practice. ML models have the potential to transform glaucoma care by enabling earlier detection, more personalized treatment, and improved patient outcomes. The widespread adoption of ML models could have a significant impact on reducing the global burden of glaucoma-related vision loss. The robustness of ML models encourages further research and development, leading to even more sophisticated and accurate tools for glaucoma management.[11-14]

Traditional methods for predicting glaucoma progression have long relied on subjective assessments of structural changes in the optic nerve head (e.g., cup-to-disc ratio) and functional changes in the visual field (e.g., visual field testing). While these methods have provided valuable insights, they possess inherent limitations that can hinder accurate

prediction and timely intervention. ML models have consistently demonstrated comparable or even superior accuracy compared to traditional methods in predicting glaucoma progression. ML models can detect subtle changes in imaging data (e.g., OCT scans) and visual field data that may not be readily apparent to human observers. These subtle changes can be early indicators of progression, allowing for earlier intervention. ML models can account for individual variability in disease progression, recognizing that not all patients follow the same trajectory. This personalized approach to prediction can lead to more accurate risk assessments. ML models can be trained on vast datasets of patient information, allowing them to identify complex patterns and relationships that may not be evident through traditional analysis. Traditional methods, particularly those relying on visual assessment of the optic nerve head, can be subjective and prone to inter-observer variability. Different clinicians may interpret the same image or visual field data differently, leading to inconsistencies in progression assessment. ML models apply standardized algorithms to analyze data, minimizing the influence of subjective interpretation. ML models provide quantitative measures of progression risk, allowing for more precise and consistent assessments. By minimizing subjectivity, ML models can reduce the potential for bias in progression assessment, ensuring that all patients are evaluated fairly. ML models can integrate diverse data sources, including structural, functional, clinical, and demographic data, to provide a more comprehensive risk profile. OCT scans provide detailed information about the thickness of the retinal nerve fiber layer (RNFL) and other structural features of the optic nerve head. Visual field tests assess the sensitivity of different areas of the visual field, providing insights into the functional impact of glaucoma. Intraocular pressure (IOP) measurements, medication history, and other clinical data can provide valuable context for understanding progression risk. Age, gender, ethnicity, and other demographic factors can also influence the risk of glaucoma progression. By integrating these diverse data sources, ML models can capture a more complete picture of the individual's risk profile, leading to more informed clinical decisions. ML models may be able to detect subtle signs of progression earlier than traditional methods, potentially leading to more timely interventions and better outcomes. ML models can identify subtle patterns in data that may be indicative of early progression, even before they become clinically apparent. ML models can be used to continuously monitor patients, providing real-time risk assessments and alerting clinicians to any changes that may warrant intervention. By detecting progression early, ML models can enable proactive management of glaucoma, potentially slowing or even halting disease progression before significant vision loss occurs.[15-17]

The promising findings of this meta-analysis highlight the transformative potential of machine learning (ML) models in revolutionizing glaucoma management. By leveraging their ability to analyze complex data, predict progression, and personalize risk assessments, ML models can empower clinicians to make more informed decisions, leading to earlier intervention, better outcomes, and a reduced burden of vision loss. ML models can play a pivotal role in risk stratification, enabling clinicians to identify individuals at high risk of glaucoma progression and tailor management strategies accordingly. This personalized approach to care can lead to more effective interventions and improved patient outcomes. ML models can analyze various data sources, including OCT scans, visual field data, clinical parameters, and demographic information, to predict the likelihood of progression for each individual. ML models can generate risk scores that quantify the probability of progression, allowing clinicians to prioritize patients based on their risk level. By identifying high-risk individuals early, ML models can enable proactive management, potentially preventing or delaying significant vision loss. High-risk individuals may require more frequent monitoring, such as visual field tests and OCT scans, to closely track changes and intervene promptly if necessary. ML

models can help guide treatment decisions, such as the choice of medication, dosage, or the need for surgical intervention, based on the individual's risk profile. ML models can identify modifiable risk factors, such as high blood pressure or smoking, allowing clinicians to provide targeted lifestyle counseling to mitigate these risks. In healthcare systems with limited resources, ML models can help prioritize care for those at highest risk, ensuring that they receive the necessary attention and interventions. ML models can be integrated into electronic health records (EHRs) to streamline clinical workflow, flagging high-risk individuals for closer monitoring and follow-up. By prioritizing care for those at highest risk, ML models can contribute to better patient outcomes and a reduced burden of glaucoma-related vision loss. ML models have the potential to detect subtle signs of glaucoma progression earlier than traditional methods, enabling earlier intervention and potentially slowing or even halting disease progression. ML models can identify subtle patterns in imaging data and visual field data that may be indicative of early progression, even before they become clinically apparent. ML models can analyze trends in data over time, identifying subtle changes that may suggest an increased risk of progression. ML models can act as an early warning system, alerting clinicians to subtle changes that may warrant further investigation or intervention. By detecting progression early, ML models can enable proactive treatment, potentially preventing or delaying significant vision loss. ML models can help guide the choice of intervention, tailoring treatment to the individual's specific needs and risk factors. ML models can be used to monitor the response to treatment, allowing clinicians to adjust treatment plans as needed to optimize outcomes. Early intervention, guided by ML models, can significantly increase the chances of preserving vision and preventing irreversible damage to the optic nerve. By preserving vision, ML models can help maintain patients' quality of life, enabling them to remain independent and engaged in their daily activities. Early intervention can help reduce the overall burden of glaucoma-related vision loss, both for individuals and for healthcare systems. ML models can contribute to personalized medicine approaches by providing individualized risk assessments and treatment recommendations based on a patient's unique characteristics and risk factors. ML models can analyze a wide range of data, including genetic information, lifestyle factors, and medical history, to provide a comprehensive assessment of an individual's risk profile. ML models can predict the likelihood of progression for each individual, taking into account their unique characteristics and risk factors. ML models can provide patient-specific insights that can inform clinical decision-making and guide personalized treatment plans. ML models can help clinicians select the most appropriate treatment options for each individual, considering their risk factors, preferences, and lifestyle. ML models can help optimize medication dosages, minimizing side effects and maximizing treatment efficacy. ML models can be used to monitor treatment response and adjust treatment plans as needed, ensuring that patients receive the most effective care. Personalized treatment, guided by ML models, can lead to enhanced treatment efficacy and better outcomes. ML models can help minimize side effects by optimizing medication dosages and selecting treatments that are most appropriate for the individual. Personalized care can lead to increased patient satisfaction and engagement in their own care. ML models can be integrated into clinical decision support systems, providing clinicians with real-time risk assessments and treatment recommendations at the point of care. ML models can automatically analyze patient data, such as OCT scans and visual field data, providing clinicians with real-time risk assessments during patient encounters. ML models can generate risk alerts, notifying clinicians of patients who may require closer monitoring or intervention. ML models can provide clinicians with evidence-based recommendations for managing patients based on their risk profiles. ML models can provide personalized treatment recommendations, considering the individual's risk factors, preferences,

and medical history. ML models can help optimize treatment plans, ensuring that patients receive the most effective care. ML models can be used to monitor treatment response and adjust treatment plans as needed, ensuring that patients receive the most appropriate care. ML models can streamline clinical workflow by automating data analysis and providing real-time risk assessments. ML models can improve the accuracy of clinical decision-making by providing evidence-based recommendations. ML models can support patient-centered care by providing personalized risk assessments and treatment recommendations.[18-20]

5. Conclusion

This meta-analysis has illuminated the considerable potential of machine learning (ML) models in predicting glaucoma progression. The synthesis of findings from six eligible studies indicates that ML models can achieve high accuracy in identifying individuals at risk of disease progression, with a pooled sensitivity of 0.81 and specificity of 0.77. The excellent discriminatory ability, represented by a pooled AUC of 0.88, underscores their potential for risk stratification and personalized glaucoma management. Despite the promising findings, it is essential to acknowledge the limitations of this study, including the relatively small number of included studies and the heterogeneity in study designs and progression definitions. Future research should focus on validating these findings in larger, more diverse datasets, standardizing the definition of glaucoma progression, and exploring the clinical utility of ML models in various healthcare settings. The integration of ML models into clinical practice holds the promise of revolutionizing glaucoma care. By enabling earlier detection, more timely interventions, and personalized treatment strategies, ML models can contribute to preserving vision and improving the quality of life for millions affected by this sight-threatening disease.

6. References

1. Pandeeswari B, Alice K. Optimized improved random forest-fostered glaucoma detection from fundus retinal images. Intern J Pattern Recognit Artif Intell. 2024.
2. Verma R, Shrinivasan L, Hiremath B. Machine learning classifiers for detection of glaucoma. IAES Int J Artif Intell (IJ-AI). 2023; 12(2): 806.
3. Jipeng T, Suma, Manjunath TC. Use of artificial intelligence & machine Learning with deep Learning for Glaucoma Detection in human eyes & its real time hardware implementation. Eur J Electr Eng Comput Sci. 2020; 4(2).
4. Prasanna R V, Shruthy R V, K A, Prajnya R, S T, Sathyan P, et al. Modeling and mitigating human annotations to design processing systems with human-in-the-loop machine learning for glaucomatous defects: The future in artificial intelligence. Indian J Ophthalmol. 2021; 69(10): 2892–4.
5. Ramesh PV, Subramaniam T, Ray P, Devadas AK, Ramesh SV, Ansar SM, et al. Utilizing human intelligence in artificial intelligence for detecting glaucomatous fundus images using human-in-the-loop machine learning. Indian J Ophthalmol. 2022; 70(4): 1131–8.
6. Lee S-D, Lee J-H, Choi Y-G, You H-C, Kang J-H, Jun C-H. Machine learning models based on the dimensionality reduction of standard automated perimetry data for glaucoma diagnosis. Artif Intell Med. 2019; 94: 110–6.
7. Aljohani A, Aburasain RY. A hybrid framework for glaucoma detection through federated machine learning and deep learning models. BMC Med Inform Decis Mak. 2024; 24(1): 115.
8. Diener R, Renz AW, Eckhard F, Segbert H, Eter N, Malcherek A, et al. Automated classification of physiologic, glaucomatous, and glaucoma-suspected optic discs using machine learning. Diagnostics (Basel). 2024; 14(11): 1073.

9. Lee SY, Lee DY, Ahn J. Evaluation of machine learning approach for surgical results of Ahmed valve implantation in patients with glaucoma. BMC Ophthalmol. 2024; 24(1): 248.
10. Barry S, Wang SY. Predicting glaucoma surgical outcomes using neural networks and machine learning on electronic health records. Transl Vis Sci Technol. 2024; 13(6): 15.
11. Karimi A, Stanik A, Kozitza C, Chen A. Integrating deep learning with electronic health records for early glaucoma detection: A multi-dimensional machine learning approach. Bioengineering (Basel). 2024; 11(6): 577.
12. Birla S, Varshney T, Singh A, Sharma A, Panigrahi A, Gupta S, et al. Machine learning-assisted prediction of trabeculectomy outcomes among patients of juvenile glaucoma by using 5-year follow-up data. Indian J Ophthalmol. 2024; 72(7): 987–93.
13. Pinheiro HM, Camilo ENR, Paranhos A Junior, Fonseca AU, Laureano GT, da Costa RM. Evaluating machine learning techniques for enhanced glaucoma screening through Pupillary Light Reflex analysis. Array (N Y). 2024; 23(100359): 100359.
14. Wang P, Shen J, Chang R, Moloney M, Torres M, Burkemper B, et al. Machine learning models for diagnosing glaucoma from retinal nerve fiber layer thickness maps. Ophthalmol Glaucoma. 2019; 2(6): 422–8.
15. Jalili J, Nadimi M, Jafari B, Esfandiari A, Sadeghi R, Ghahari P, et al. Vessel density features of optical coherence tomography angiography for classification of glaucoma using machine learning. J Glaucoma. 2023; 32(12): 1006–10.
16. Kurysheva NI, Pomerantsev AL, Rodionova OY, Sharova GA. Comparison of lens extraction versus laser iridotomy on anterior segment, choroid, and intraocular pressure in primary angle closure using Machine Learning. J Glaucoma. 2023; 32(6): e43–55.
17. Huang X, Poursoroush A, Sun J, Boland MV, Johnson CA, Yousefi S. Identifying factors associated with fast visual field progression in patients with ocular hypertension based on unsupervised machine learning. J Glaucoma. 2024; 33(11): 815–22.
18. Wu C-W, Huang T-Y, Liou Y-C, Chen S-H, Wu K-Y, Tseng H-Y. Recognition of glaucomatous fundus images using machine learning methods based on optic nerve head topographic features. J Glaucoma. 2024; 33(8): 601–6.
19. Lin M, Liu L, Gorden M, Kass M, Van Tassel S, Wang F, et al. Multi-scale Multi-structure Siamese Network (MMSNet) for primary open-angle glaucoma prediction. Mach Learn Med Imaging. 2022; 13583: 436–45.
20. Sigut J, Fumero F, Arnay R, Estévez J, Díaz-Alemán T. Interpretable surrogate models to approximate the predictions of convolutional neural networks in glaucoma diagnosis. Mach Learn Sci Technol. 2023; 4(4): 045024.